ClinicalTrialsFinder

HRD-positive/HER2-negative Advanced Breast Cancer Clinical Trials in Guangzhou, Guangdong

1 recruitingGuangzhou, Guangdong, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Fludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University200 enrolled1 locationNCT06255392